NCT04631406View on ClinicalTrials.gov

A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2029

Conditions
Ischemic Stroke
Interventions
BIOLOGICAL

Neural Stem Cells

NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke

Trial Locations (1)

94305

Stanford Health Center, Stanford

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Gary Steinberg, MD, PhD

OTHER